Trends in outcomes and racial disparities in adult hospitalizations for immune thrombocytopenia over a decade.
Hematology
ITP
Platelets
Thrombocytopenia
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
15
03
2023
accepted:
19
04
2023
medline:
14
6
2023
pubmed:
6
5
2023
entrez:
5
5
2023
Statut:
ppublish
Résumé
Immune thrombocytopenia (ITP) is a diagnosis of exclusion characterized by a low platelet count in patients for whom other etiologies have been ruled out. It occurs due to autoimmune-mediated platelet destruction and thrombopoietin deficiency. ITP is a rare hematologic disorder in adults, and scarce information exists on the hospitalization outcomes among these patients. To address this knowledge gap, we conducted a nationwide population-based study from 2010 to 2019 using the National Inpatient Sample. We found a trend toward an increase in the annual admissions for ITP (from 392.2 to 417.3, p = 0.07). There was a decrease in mortality exclusively for White patients over the period studied (p = 0.03), which was not seen in Black or Hispanic patients. There was an increase in total charges adjusted for inflation for all subgroups (p < 0.01). Length of stay decreased during the decade analyzed (p < 0.01) for the total population and most subgroups. The rates of epistaxis and melena increased (p < 0.01), while rates of intracranial hemorrhage and hematemesis did not change significantly. Advances have been made in the ITP management over the past decade. However, this has not resulted in a decrease in the number of hospitalizations or total healthcare charges during hospitalization. Furthermore, a decrease in mortality was observed in White patients but not in other races. Prospective studies are needed to better characterize the financial burden of the disease, as well as to investigate racial variability in access to care, disease behavior, and response to treatment.
Identifiants
pubmed: 37147362
doi: 10.1007/s00277-023-05249-8
pii: 10.1007/s00277-023-05249-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1677-1686Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Kistangari G, McCrae KR (2013) Immune thrombocytopenia. Hematol Oncol Clin North Am 27:495–520
doi: 10.1016/j.hoc.2013.03.001
pubmed: 23714309
Moulis G, Germain J, Comont T et al (2017) Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. Am J Hematol 92:493–500
doi: 10.1002/ajh.24702
pubmed: 28240787
Terrell DR, Beebe LA, Neas BR et al (2012) Prevalence of primary immune thrombocytopenia in Oklahoma. Am J Hematol 87:848–852
doi: 10.1002/ajh.23262
pubmed: 22674643
pmcid: 3429719
Song F, Al-Samkari H (2021) Management of adult patients with immune thrombocytopenia (ITP): a review on current guidance and experience from clinical practice. J Blood Med 12:653–664
doi: 10.2147/JBM.S259101
pubmed: 34345191
pmcid: 8323851
Okubo Y, Handa A (2018) Nationwide trend analysis of pediatric inpatients with immune thrombocytopenia in the United States. J Pediatr Hematol Oncol 40:e140–e144
doi: 10.1097/MPH.0000000000001083
pubmed: 29334536
Walker LS, Kim TO, Grimes AB et al (2019) Racial variation in ITP prevalence and rate of chronic disease suggests biological differences. Blood 134:387–387
doi: 10.1182/blood-2019-130418
Healthcare Cost and Utilization Project Introduction to the HCUP National Inpatient Sample (NIS). The National (Nationwide) Inpatient Sample database documentation. Agency for Healthcare Research and Quality https://www.hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2018.jsp November 2020
Houchens R, Ross D, Elixhauser A, Jiang J (2014) 2014 Nationwide Inpatient Sample (NIS) redesign final report. HCUP Methods Series Report # 2014-04. U.S. Agency for Healthcare Research and Quality, http://www.hcup-us.ahrq.gov/reports/methods/methods.jsp
Elixhauser A, Heslin KC (2017) Recommendations for reporting trends using ICD-9-CM and ICD-10-CM/PCS data. US Agency for Healthcare Research and Quality , September 2022, https://www.hcup-us.ahrq.gov/datainnovations/HCUP_RecomForReportingTrends_070517.pdf
Sundararajan V, Quan H, Halfon P et al (2007) Cross-national comparative performance of three versions of the ICD-10 Charlson index. Med Care 45:1210–1215
doi: 10.1097/MLR.0b013e3181484347
pubmed: 18007172
Barrett M, Coffey R, Levit (2020) Population denominator data sources and data for use with the HCUP databases (updated with 2019 population data) 2020 HCUP Methods Series Report # 2020-02. US Agency for Healthcare Research and Quality , September 2022, https://www.hcup-us.ahrq.gov/reports/methods/2020-02.pdf
Kim HJ, Fay MP, Feuer EJ et al (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:335–351
doi: 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z
pubmed: 10649300
Zoorob RJ, Salemi JL, Mejia de Grubb MC et al (2019) A nationwide study of breast cancer, depression, and multimorbidity among hospitalized women and men in the United States. Breast Cancer Res Treat 174:237–248
doi: 10.1007/s10549-018-5059-5
pubmed: 30465155
Ikedionwu CA, Dongarwar D, Williams C et al (2021) Trends and risk factors for Leishmaniasis among reproductive aged women in the United States. Int J MCH AIDS 10:166–173
doi: 10.21106/ijma.478
pubmed: 34386298
pmcid: 8346677
Dunn A, Grosse SD, Zuvekas SH (2018) Adjusting health expenditures for inflation: a review of measures for health services research in the United States. Health Serv Res 53:175–196
doi: 10.1111/1475-6773.12612
pubmed: 27873305
Cooper N, Ghanima W (2019) Immune thrombocytopenia. N Engl J Med 381:945–955
doi: 10.1056/NEJMcp1810479
pubmed: 31483965
Neunert C, Terrell DR, Arnold DM et al (2019) American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3:3829–3866
doi: 10.1182/bloodadvances.2019000966
pubmed: 31794604
pmcid: 6963252
Provan D, Arnold DM, Bussel JB et al (2019) Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3:3780–3817
doi: 10.1182/bloodadvances.2019000812
pubmed: 31770441
pmcid: 6880896
Finianos A, Mujadzic H, Peluso H et al (2021) Temporal trends and outcome of splenectomy in adults with immune thrombocytopenia in the USA. Ann Hematol 100:941–952
doi: 10.1007/s00277-021-04449-4
pubmed: 33560468
Agarwal N, Mangla A (2021) Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review. Ther Adv Hematol 12:20406207211001139
doi: 10.1177/20406207211001139
pubmed: 33796239
pmcid: 7983475
Goshua G, Sinha P, Kunst N et al (2023) Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia. Am J Hematol 98:122–130
doi: 10.1002/ajh.26497
pubmed: 35147241
Li X, Sharma A, Zhang X et al (2015) Cost per treatment success of thrombopoietin receptor agonists Vs ‘watch and rescue’ strategy for treating adult non-splenectomized patients with chronic immune thrombocytopenia: a US payer perspective. Blood 126:4461–4461
doi: 10.1182/blood.V126.23.4461.4461
Bane M, Gajewski SS, Reilly AW, et al. 2021 Health insurance coverage in the United States: 2021, February 2023, https://www.census.gov/content/dam/Census/library/publications/2022/demo/p60-278.pdf .